JP2013512280A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013512280A5 JP2013512280A5 JP2012542161A JP2012542161A JP2013512280A5 JP 2013512280 A5 JP2013512280 A5 JP 2013512280A5 JP 2012542161 A JP2012542161 A JP 2012542161A JP 2012542161 A JP2012542161 A JP 2012542161A JP 2013512280 A5 JP2013512280 A5 JP 2013512280A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- substituted
- compound
- alkylene
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26556309P | 2009-12-01 | 2009-12-01 | |
| US61/265,563 | 2009-12-01 | ||
| US36411610P | 2010-07-14 | 2010-07-14 | |
| US61/364,116 | 2010-07-14 | ||
| PCT/US2010/058572 WO2011068881A1 (en) | 2009-12-01 | 2010-12-01 | Novel tricyclic compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014171336A Division JP5985557B2 (ja) | 2009-12-01 | 2014-08-26 | 新規な三環式化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013512280A JP2013512280A (ja) | 2013-04-11 |
| JP2013512280A5 true JP2013512280A5 (https=) | 2014-01-23 |
| JP5607174B2 JP5607174B2 (ja) | 2014-10-15 |
Family
ID=44070404
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012542161A Active JP5607174B2 (ja) | 2009-12-01 | 2010-12-01 | 新規な三環式化合物 |
| JP2014171336A Expired - Fee Related JP5985557B2 (ja) | 2009-12-01 | 2014-08-26 | 新規な三環式化合物 |
| JP2016151711A Expired - Fee Related JP6298114B2 (ja) | 2009-12-01 | 2016-08-02 | 新規な三環式化合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014171336A Expired - Fee Related JP5985557B2 (ja) | 2009-12-01 | 2014-08-26 | 新規な三環式化合物 |
| JP2016151711A Expired - Fee Related JP6298114B2 (ja) | 2009-12-01 | 2016-08-02 | 新規な三環式化合物 |
Country Status (41)
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5748659B2 (ja) * | 2008-06-10 | 2015-07-15 | アッヴィ・インコーポレイテッド | 新規な三環式化合物 |
| AU2010237859A1 (en) * | 2009-04-14 | 2011-11-03 | Astellas Pharma Inc. | Fused pyrrolopyridine derivative |
| PE20121336A1 (es) * | 2009-12-01 | 2012-11-03 | Abbvie Inc | Nuevos compuestos triciclicos |
| KR20120102724A (ko) * | 2009-12-01 | 2012-09-18 | 아보트 러보러터리즈 | 신규한 트리사이클릭 화합물 |
| EP2523957A1 (en) | 2010-01-12 | 2012-11-21 | F. Hoffmann-La Roche AG | Tricyclic heterocyclic compounds, compositions and methods of use thereof |
| WO2012127506A1 (en) | 2011-03-22 | 2012-09-27 | Advinus Therapeutics Limited | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
| EP2699572B1 (en) | 2011-04-21 | 2016-08-10 | Origenis GmbH | Heterocyclic compounds as kinase inhibitors |
| WO2013007765A1 (en) * | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Fused tricyclic compounds for use as inhibitors of janus kinases |
| AU2012295802B2 (en) | 2011-08-12 | 2017-03-30 | Nissan Chemical Industries, Ltd. | Tricyclic heterocyclic compounds and JAK inhibitors |
| US20130072470A1 (en) * | 2011-09-21 | 2013-03-21 | Abbvie Inc. | Novel tricyclic compounds |
| CN102516146B (zh) * | 2011-11-24 | 2013-10-02 | 爱斯特（成都）生物制药有限公司 | 5位为氮的四元氮杂螺环衍生物及其制备方法和用途 |
| ES2704744T3 (es) | 2012-06-13 | 2019-03-19 | Incyte Holdings Corp | Compuestos tricíclicos sustituidos como inhibidores de FGFR |
| IN2015DN02008A (https=) * | 2012-09-21 | 2015-08-14 | Advinus Therapeutics Ltd | |
| US10000482B2 (en) | 2012-10-19 | 2018-06-19 | Origenis Gmbh | Kinase inhibitors |
| JP6248948B2 (ja) * | 2013-02-08 | 2017-12-20 | 日産化学工業株式会社 | ３環性ピロロピリジン化合物及びｊａｋ阻害剤 |
| CU24275B1 (es) | 2013-02-22 | 2017-10-05 | Pfizer | Derivados de cicloalquilo pirrolo [2,3-d] pirimidina-4-il amino útiles como inhibidores de quinasas janus relacionadas y composiciones farmacéuticas que contienen tales compuestos |
| WO2014134281A1 (en) | 2013-02-28 | 2014-09-04 | Full Spectrum Laboratories Limited | Biosynthesis of cannabinoids |
| CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| EP3060234A1 (en) * | 2013-10-24 | 2016-08-31 | AbbVie Inc. | Jak1 selective inhibitor and uses thereof |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| EP3129373B1 (en) * | 2014-04-11 | 2021-09-01 | Taipei Medical University | Histone deacetylase inhibitors |
| WO2015174376A1 (ja) | 2014-05-14 | 2015-11-19 | 日産化学工業株式会社 | ３環性化合物及びｊａｋ阻害剤 |
| CA2955229C (en) | 2014-07-17 | 2020-03-10 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| EP3180344B1 (en) | 2014-08-12 | 2019-09-18 | Pfizer Inc | Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase |
| US9394510B2 (en) | 2014-08-25 | 2016-07-19 | Full Spectrum Laboratories Limited | Apparatus and methods for the simultaneous production of compounds |
| WO2016064873A1 (en) | 2014-10-20 | 2016-04-28 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11780848B2 (en) | 2015-10-16 | 2023-10-10 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof |
| EP3362455A1 (en) | 2015-10-16 | 2018-08-22 | AbbVie Inc. | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
| US12570664B2 (en) * | 2015-10-16 | 2026-03-10 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US12365689B2 (en) | 2015-10-16 | 2025-07-22 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| EP3402798B1 (en) | 2016-01-14 | 2021-04-28 | Handok Inc. | Compounds antagonizing a3 adenosine receptor, method for preparing them, and medical-use thereof |
| EP3433615A1 (en) | 2016-03-21 | 2019-01-30 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods for diagnosis and treatment of solar lentigo |
| JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
| LT3555097T (lt) | 2016-12-16 | 2022-08-25 | Janssen Pharmaceutica Nv | Imidazo[4,5-d]pirolo[2,3-b]piridino junginiai kaip janus kinazės inhibitoriai |
| CN120661512A (zh) | 2017-03-09 | 2025-09-19 | 艾伯维公司 | 治疗克罗恩病和溃疡性结肠炎的方法 |
| US11564922B2 (en) | 2017-03-09 | 2023-01-31 | Abbvie Inc. | Methods of treating crohn's disease and ulcerative colitis |
| WO2018167283A1 (en) | 2017-03-17 | 2018-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling |
| US10364245B2 (en) | 2017-06-07 | 2019-07-30 | Chiesi Farmaceutici S.P.A. | Kinase inhibitors |
| WO2019057103A1 (zh) * | 2017-09-21 | 2019-03-28 | 上海华汇拓医药科技有限公司 | Jak激酶抑制剂及其制备方法和在医药领域的应用 |
| AU2019234574A1 (en) | 2018-03-12 | 2020-09-03 | Abbvie Inc. | Inhibitors of tyrosine kinase 2 mediated signaling |
| CR20200590A (es) | 2018-05-04 | 2021-04-26 | Incyte Corp | Formas sólidas de un inhibidor de fgfr y procesos para prepararlas |
| MA52493A (fr) | 2018-05-04 | 2021-03-10 | Incyte Corp | Sels d'un inhibiteur de fgfr |
| TW202016110A (zh) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Ｊａｋ激酶家族之小分子抑制劑 |
| CN110872250B (zh) * | 2018-08-31 | 2023-01-10 | 苏州鹏旭医药科技有限公司 | 两种化合物及其制备方法和在合成乌西替尼中的用途 |
| EP3845521B1 (en) | 2018-08-31 | 2024-11-06 | Suzhou Pengxu Pharmatech Co., Ltd. | Synthesis methods for upadacitinib and intermediate thereof |
| EP3856742B1 (en) * | 2018-11-01 | 2024-10-02 | Lynk Pharmaceuticals Co. Ltd. | Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| CN111217819B (zh) * | 2018-11-27 | 2021-05-14 | 杭州科巢生物科技有限公司 | 乌帕替尼的合成方法 |
| WO2020115212A1 (en) | 2018-12-05 | 2020-06-11 | Lek Pharmaceuticals D.D. | Crystalline phosphate salt of selective jak1 inhibitor upadacitinib |
| WO2020115213A1 (en) | 2018-12-07 | 2020-06-11 | Lek Pharmaceuticals D.D. | Solvate of a selective jak1 inhibitor |
| CN109761885B (zh) * | 2019-02-21 | 2020-06-26 | 北京悦康科创医药科技股份有限公司 | 一种阿加曲班异构体杂质的拆分方法 |
| US20210380596A1 (en) * | 2019-03-01 | 2021-12-09 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Upadacitinib crystal form and preparation method therefor and use thereof |
| MA55201A (fr) | 2019-03-05 | 2022-01-12 | Incyte Corp | Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire |
| KR102737181B1 (ko) | 2019-03-14 | 2024-12-02 | 상하이 시너지 파마슈티컬 사이언시스 코., 엘티디. | Jak 억제제 및 그 제조방법과 의약분야에서의 응용 |
| WO2020202183A1 (en) | 2019-03-29 | 2020-10-08 | Mylan Laboratories Limited | The process for the preparation of upadacitinib and its intermediates |
| CN111909160B (zh) * | 2019-05-09 | 2024-05-28 | 苏州鹏旭医药科技有限公司 | 一种乌帕替尼盐类化合物及其制备方法 |
| US12582650B2 (en) | 2019-07-26 | 2026-03-24 | Guangzhou Yufan Nantu Biotechnologies Co., Ltd | IRAK4 kinase inhibitor and preparation method therefor |
| CN110938048B (zh) * | 2019-12-02 | 2023-03-28 | 四川大学 | 路易酸催化的插入反应高效合成二氢呋喃衍生物 |
| BR112022010664A2 (pt) | 2019-12-04 | 2022-08-16 | Incyte Corp | Derivados de um inibidor de fgfr |
| US12552746B2 (en) | 2019-12-19 | 2026-02-17 | Curia Spain, S.A.U. | Process and intermediates for the preparation of upadacitinib |
| CN111007184B (zh) * | 2019-12-30 | 2023-05-16 | 天津天士力圣特制药有限公司 | 一种4-甲基哌嗪-1-甲酰氯盐酸盐含量的检测方法 |
| WO2021176473A1 (en) | 2020-03-05 | 2021-09-10 | Mylan Laboratories Limited | A process for the preparation of upadacitinib and its intermediates |
| US11718622B2 (en) | 2020-03-16 | 2023-08-08 | Exelixis Inc. | Heterocyclic adenosine receptor antagonists |
| US20210371389A1 (en) * | 2020-04-24 | 2021-12-02 | Kansas Soybean Commission | One-step synthesis of soybean polyols |
| WO2021244323A1 (zh) * | 2020-06-05 | 2021-12-09 | 苏州科睿思制药有限公司 | 一种乌帕替尼的晶型及其制备方法和用途 |
| CN114206878B (zh) | 2020-07-08 | 2024-04-19 | 苏州科睿思制药有限公司 | 乌帕替尼的晶型及其制备方法和用途 |
| WO2022044037A1 (en) | 2020-08-24 | 2022-03-03 | Mylan Laboratories Limited | An improved process for the preparation of upadacitinib intermediate |
| WO2022054005A1 (en) * | 2020-09-14 | 2022-03-17 | Galderma Holding SA | Novel jak inhibitor compounds, method for synthesizing same and use thereof |
| US20230374011A1 (en) * | 2020-10-08 | 2023-11-23 | Unichem Laboratories Ltd. | Substituted tricyclic compounds |
| CN112578034B (zh) * | 2020-11-04 | 2022-02-11 | 广东众生睿创生物科技有限公司 | 一种手性胺小分子及其盐的质量控制方法 |
| CN114790208B (zh) * | 2021-01-26 | 2024-06-07 | 珠海宇繁生物科技有限责任公司 | 一种irak4激酶抑制剂及其制备方法 |
| BR112023018286A2 (pt) | 2021-03-11 | 2023-10-31 | Janssen Pharmaceutica Nv | Lorpucitinib para uso no tratamento de distúrbios mediados por jak |
| WO2022217257A1 (en) * | 2021-04-07 | 2022-10-13 | Abbvie Inc. | Cocrystals of upadacitinib |
| CN113200967B (zh) * | 2021-05-07 | 2022-05-24 | 中国人民解放军陆军军医大学 | 吲哚苯醌类化合物、其制备方法及其应用 |
| CN115340528A (zh) * | 2021-05-13 | 2022-11-15 | 上海翊石医药科技有限公司 | 一种具有抗肿瘤活性的化合物及其用途 |
| CN113603693B (zh) * | 2021-07-13 | 2022-08-26 | 陕西丽彩药业有限公司 | 一种2-溴-5-对甲苯磺酰基-5H-吡咯并[2,3-b]吡嗪的制备方法 |
| CN114380837B (zh) * | 2021-12-27 | 2023-06-30 | 上海邈金医药科技有限公司 | 一种具有Janus激酶抑制活性的化合物、包括该化合物的组合物及其应用 |
| EP4215196A1 (en) | 2022-01-24 | 2023-07-26 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor |
| US12487299B2 (en) | 2022-06-20 | 2025-12-02 | Shanghai United Imaging Healthcare Co., Ltd. | Magnetic resonance imaging devices and radiation therapy systems including the magnetic resonance imaging devices |
| CN116836171B (zh) * | 2023-06-30 | 2024-06-04 | 凌科药业(杭州)有限公司 | 一种磺酰胺类化合物及其应用 |
| WO2025102268A1 (en) * | 2023-11-15 | 2025-05-22 | Lynk Pharmaceuticals Co. Ltd. | Solid state forms, pharmaceutical compositions, preparation methods and use thereof |
| CN117285537B (zh) * | 2023-11-27 | 2024-02-06 | 中节能万润股份有限公司 | 一种乌帕替尼的制备方法 |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB716327A (en) | 1951-09-05 | 1954-10-06 | Ici Ltd | New heterocyclic compounds |
| US3663559A (en) | 1969-12-03 | 1972-05-16 | Union Carbide Corp | Preparation of oxo-furo-pyridines from furylvinyl isocyanates |
| ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| US4053474A (en) * | 1976-04-21 | 1977-10-11 | E. R. Squibb & Sons, Inc. | Pyrazolo[4,3-e][1,2,4]triazolo[4,3-c]pyrimidine |
| US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
| ES2152207T3 (es) | 1989-10-20 | 2001-02-01 | Kyowa Hakko Kogyo Kk | Derivados condensados de la purina. |
| AU651569B2 (en) | 1990-01-11 | 1994-07-28 | Isis Pharmaceuticals, Inc. | Compositions and methods for detecting and modulating RNA activity and gene expression |
| US6262241B1 (en) | 1990-08-13 | 2001-07-17 | Isis Pharmaceuticals, Inc. | Compound for detecting and modulating RNA activity and gene expression |
| WO1992009304A1 (en) | 1990-11-26 | 1992-06-11 | Recker Robert R | Treatment for osteoporosis using growth hormone release factor (grf) in combination with parathyroid hormone (pth) |
| EP1097945B1 (en) | 1991-03-18 | 2007-07-04 | New York University | Monoclonal and chimeric antibody specific for human tumor necrosis factor |
| AU657986B2 (en) | 1991-06-14 | 1995-03-30 | Pharmacia & Upjohn Company | Imidazo(1,5-a)quinoxalines |
| US5212310A (en) | 1991-12-19 | 1993-05-18 | Neurogen Corporation | Certain aryl fused imidazopyrimidines; a new class of GABA brain receptor ligands |
| US5266698A (en) | 1992-04-30 | 1993-11-30 | Neurogen Corporation | Certain aryl and cycloalkyl fused imidazopyrazinediones; a new class of GABA brain receptor ligands |
| US5306819A (en) | 1992-08-27 | 1994-04-26 | Neurogen Corporation | Certain aryl a cycloalkyl fused imidazopyrazinols; and new class of GABA brain receptor ligands |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| WO1994019351A1 (en) | 1993-02-26 | 1994-09-01 | Schering Corporation | 2-benzyl-polycyclic guanine derivatives and process for preparing them |
| US5736540A (en) | 1993-07-29 | 1998-04-07 | American Cyanamid Company | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists |
| US5733905A (en) | 1993-07-29 | 1998-03-31 | American Cyanamid Company | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists |
| IL112248A0 (en) * | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| US5547975A (en) | 1994-09-20 | 1996-08-20 | Talley; John J. | Benzopyranopyrazolyl derivatives for the treatment of inflammation |
| RU2158127C2 (ru) | 1994-12-23 | 2000-10-27 | Варнер-Ламберт Компани | Способы ингибирования тирозинкиназы рецептора эпидермального фактора роста, азотсодержащие трициклические соединения, фармацевтическая композиция, предназначенная для введения ингибитора тирозинкиназы рецептора эпидермального фактора роста, например, erb-b2, erb-b3 или erb-b4, и противозачаточная композиция |
| US5521173A (en) | 1995-01-17 | 1996-05-28 | American Home Products Corporation | Tricyclic benzazepine vasopressin antagonists |
| US5753648A (en) | 1995-01-17 | 1998-05-19 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| US5763137A (en) | 1995-08-04 | 1998-06-09 | Agfa-Gevaert, N.V. | Method for making a lithographic printing plate |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| ATE430149T1 (de) | 1998-03-04 | 2009-05-15 | Bristol Myers Squibb Co | Heterocyclen substituierte imidazopyrazine als protein- tyrosin-kinase-inhibitoren |
| US6448253B1 (en) | 1998-09-16 | 2002-09-10 | King Pharmaceuticals Research And Development, Inc. | Adenosine A3 receptor modulators |
| CO5271670A1 (es) | 1999-10-29 | 2003-04-30 | Pfizer Prod Inc | Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas |
| TWI271406B (en) | 1999-12-13 | 2007-01-21 | Eisai Co Ltd | Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same |
| JP4100865B2 (ja) * | 1999-12-13 | 2008-06-11 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 三環式縮合異項環化合物、その製造法およびその医薬 |
| MXPA03001186A (es) | 2000-08-07 | 2004-04-20 | Neurogen Corp | Compuestos heterociclicos como ligandos del receptor acido gamma aminobutirico (gabaa). |
| GB0115393D0 (en) * | 2001-06-23 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| GB0124299D0 (en) * | 2001-10-10 | 2001-11-28 | Astrazeneca Ab | Crystal structure of enzyme and uses thereof |
| US20040127492A1 (en) | 2002-02-19 | 2004-07-01 | Pharmacia Corporation | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 |
| TW200400034A (en) | 2002-05-20 | 2004-01-01 | Bristol Myers Squibb Co | Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors |
| AU2003268184A1 (en) * | 2002-08-23 | 2004-03-11 | Chiron Corporation | Pyrrole based inhibitors of glycogen synthase kinase 3 |
| EP1590341B1 (en) * | 2003-01-17 | 2009-06-17 | Warner-Lambert Company LLC | 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation |
| US7176214B2 (en) | 2003-05-21 | 2007-02-13 | Bristol-Myers Squibb Company | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
| US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| TW200524864A (en) * | 2003-11-10 | 2005-08-01 | Wyeth Corp | Sulfonyltetrahydro-3H-benzo(E)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands |
| EP1753428A4 (en) * | 2004-05-14 | 2010-09-15 | Abbott Lab | INHIBITORS OF KINASES AS THERAPEUTIC AGENTS |
| AR049300A1 (es) * | 2004-06-15 | 2006-07-12 | Schering Corp | Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos |
| DE502005008916D1 (de) | 2004-07-23 | 2010-03-11 | Medicines Co Leipzig Gmbh | Substituierte pyridoä3',2':4,5üthienoä3,2-düpyrimidine und pyridoä3',2':4,5üfuroä3,2-dü-pyrimidine zur verwendung als inhibitoren der pda-4 und/oder tnf-alpha freisetzung |
| EP1814883A1 (en) | 2004-11-22 | 2007-08-08 | Vertex Pharmaceuticals Incorporated | Bicyclic inhibitors or rho kinase |
| DE602006014502D1 (de) * | 2005-01-14 | 2010-07-08 | Janssen Pharmaceutica Nv | Pyrazolopyrimidine als zellzyklus-kinasehemmer |
| EP1846408B1 (en) | 2005-01-14 | 2013-03-20 | Janssen Pharmaceutica NV | 5-membered annelated heterocyclic pyrimidines as kinase inhibitors |
| US20060183758A1 (en) | 2005-02-17 | 2006-08-17 | Cb Research And Development, Inc. | Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans |
| JP2008538119A (ja) * | 2005-04-01 | 2008-10-09 | コーリー ファーマシューティカル グループ，インコーポレーテッド | ピラゾロ［３，４−ｃ］キノリン類、ピラゾロ［３，４−ｃ］ナフチリジン類、これらの類似体、および方法 |
| US7737279B2 (en) * | 2005-05-10 | 2010-06-15 | Bristol-Myers Squibb Company | 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same |
| US7593820B2 (en) | 2005-05-12 | 2009-09-22 | Cytopia Research Pty Ltd | Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof |
| WO2007007919A2 (en) * | 2005-07-14 | 2007-01-18 | Astellas Pharma Inc. | Heterocyclic janus kinase 3 inhibitors |
| CN101223168A (zh) * | 2005-07-14 | 2008-07-16 | 安斯泰来制药株式会社 | Janus激酶3的杂环类抑制剂 |
| EP2251341A1 (en) * | 2005-07-14 | 2010-11-17 | Astellas Pharma Inc. | Heterocyclic Janus kinase 3 inhibitors |
| MX2008002114A (es) | 2005-07-21 | 2008-04-17 | Ardea Biosciences Inc | Inhibidores de n-(arilamino)-sulfonamida de mek. |
| MX2008002165A (es) * | 2005-08-16 | 2008-04-29 | Irm Llc | Compuestos y composiciones como inhibidores de la proteina cinasa. |
| WO2007035935A1 (en) | 2005-09-23 | 2007-03-29 | Coley Pharmaceutical Group, Inc. | METHOD FOR 1H-IMIDAZO[4,5-c]PYRIDINES AND ANALOGS THEREOF |
| CN101321760A (zh) * | 2005-10-06 | 2008-12-10 | 先灵公司 | 作为蛋白激酶抑制剂的吡唑并嘧啶 |
| US8518964B2 (en) | 2005-11-22 | 2013-08-27 | Merck Sharp & Dohme Corp. | Tricyclic compounds useful as inhibitors of kinases |
| TW200801008A (en) | 2005-12-29 | 2008-01-01 | Abbott Lab | Protein kinase inhibitors |
| TW200811173A (en) * | 2006-02-15 | 2008-03-01 | Abbott Lab | Pyrazoloquinolones are potent PART inhibitors |
| EP2049518B1 (en) | 2006-05-31 | 2011-08-31 | Takeda San Diego, Inc. | Indazole and isoindole derivatives as glucokinase activating agents. |
| US7629346B2 (en) | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
| US20080090834A1 (en) | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| US8063225B2 (en) | 2006-08-14 | 2011-11-22 | Chembridge Corporation | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
| WO2008063287A2 (en) | 2006-10-06 | 2008-05-29 | Abbott Laboratories | Novel imidazothiazoles and imidazoxazoles |
| EP2123651A4 (en) * | 2007-01-12 | 2011-05-04 | Astellas Pharma Inc | CONDENSED PYRIDINE COMPOUND |
| EP2108019A2 (en) * | 2007-01-30 | 2009-10-14 | Biogen Idec MA, Inc. | 1-h-pyrazolo[3,4b]pyrimidine derivatives and their use as modulators of mitotic kinases |
| WO2008112695A2 (en) | 2007-03-12 | 2008-09-18 | Irm Llc | Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment |
| US7691869B2 (en) * | 2007-03-30 | 2010-04-06 | King Pharmaceuticals Research And Development, Inc. | Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity |
| EP2145012A2 (en) | 2007-04-04 | 2010-01-20 | F. Hoffmann-Roche AG | Microbial reduction of an acetoxyketone |
| WO2009005675A1 (en) * | 2007-06-28 | 2009-01-08 | Abbott Laboratories | Novel triazolopyridazines |
| UA99731C2 (ru) | 2007-07-30 | 2012-09-25 | Ардеа Биосайенсис, Инк | Кристаллические полиморфные формы n-(ариламино)сульфонамидов как ингибиторы мэк, композиция (варианты) и применение |
| UY31631A1 (es) * | 2008-02-06 | 2009-09-30 | Nuevos derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino, sales de los mismos, procesos para su preparacion, composiciones farmacéuticas que los comprenden y aplicaciones | |
| JP5368485B2 (ja) | 2008-02-25 | 2013-12-18 | エフ．ホフマン−ラ ロシュ アーゲー | ピロロピラジンキナーゼインヒビター |
| CA2716223A1 (en) | 2008-02-25 | 2009-09-03 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine kinase inhibitors |
| ATE522536T1 (de) | 2008-02-25 | 2011-09-15 | Hoffmann La Roche | Pyrrolopyrazin-kinasehemmer |
| WO2009108827A1 (en) | 2008-02-29 | 2009-09-03 | Wyeth | Fused tricyclic pyrazolo[1, 5-a]pyrimidines, methods for preparation and uses thereof |
| JP5748659B2 (ja) | 2008-06-10 | 2015-07-15 | アッヴィ・インコーポレイテッド | 新規な三環式化合物 |
| CN102143746A (zh) * | 2008-07-03 | 2011-08-03 | 埃克塞利希斯股份有限公司 | Cdk 调节剂 |
| AU2010237859A1 (en) * | 2009-04-14 | 2011-11-03 | Astellas Pharma Inc. | Fused pyrrolopyridine derivative |
| US8361962B2 (en) * | 2009-07-27 | 2013-01-29 | Roche Palo Alto Llc | Tricyclic inhibitors of JAK |
| KR20120102724A (ko) | 2009-12-01 | 2012-09-18 | 아보트 러보러터리즈 | 신규한 트리사이클릭 화합물 |
| PE20121336A1 (es) | 2009-12-01 | 2012-11-03 | Abbvie Inc | Nuevos compuestos triciclicos |
| US8637529B2 (en) | 2010-06-11 | 2014-01-28 | AbbYie Inc. | Pyrazolo[3,4-d]pyrimidine compounds |
| WO2012149280A2 (en) | 2011-04-29 | 2012-11-01 | Abbott Laboratories | Novel tricyclic compounds |
| US20130072470A1 (en) | 2011-09-21 | 2013-03-21 | Abbvie Inc. | Novel tricyclic compounds |
| EP3060234A1 (en) | 2013-10-24 | 2016-08-31 | AbbVie Inc. | Jak1 selective inhibitor and uses thereof |
| EP3362455A1 (en) | 2015-10-16 | 2018-08-22 | AbbVie Inc. | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
-
2010
- 2010-12-01 PE PE2012000745A patent/PE20121336A1/es active IP Right Grant
- 2010-12-01 TW TW099141754A patent/TWI500620B/zh active
- 2010-12-01 RS RS20170760A patent/RS56317B1/sr unknown
- 2010-12-01 CA CA2781891A patent/CA2781891C/en active Active
- 2010-12-01 SG SG2012040465A patent/SG181472A1/en unknown
- 2010-12-01 EP EP17171010.6A patent/EP3266786A1/en not_active Withdrawn
- 2010-12-01 AR ARP100104438A patent/AR079234A1/es active IP Right Grant
- 2010-12-01 MY MYPI2012700314A patent/MY167076A/en unknown
- 2010-12-01 UY UY0001033071A patent/UY33071A/es active IP Right Grant
- 2010-12-01 HU HUE10835061A patent/HUE033099T2/en unknown
- 2010-12-01 KR KR1020187025442A patent/KR20180101626A/ko not_active Withdrawn
- 2010-12-01 HR HRP20171175TT patent/HRP20171175T1/hr unknown
- 2010-12-01 NZ NZ600161A patent/NZ600161A/en unknown
- 2010-12-01 ES ES10835061.2T patent/ES2637588T3/es active Active
- 2010-12-01 CN CN201810448360.6A patent/CN108774237A/zh active Pending
- 2010-12-01 WO PCT/US2010/058572 patent/WO2011068881A1/en not_active Ceased
- 2010-12-01 AU AU2010326108A patent/AU2010326108C1/en active Active
- 2010-12-01 CN CN201810902092.0A patent/CN109053742B/zh active Active
- 2010-12-01 CR CR20170159A patent/CR20170159A/es unknown
- 2010-12-01 TW TW106122295A patent/TW201802091A/zh unknown
- 2010-12-01 LT LTEP10835061.2T patent/LT2506716T/lt unknown
- 2010-12-01 JP JP2012542161A patent/JP5607174B2/ja active Active
- 2010-12-01 US US12/958,115 patent/US8426411B2/en not_active Ceased
- 2010-12-01 DK DK10835061.2T patent/DK2506716T3/en active
- 2010-12-01 EP EP10835061.2A patent/EP2506716B1/en active Active
- 2010-12-01 BR BR112012013349-7A patent/BR112012013349B1/pt active IP Right Grant
- 2010-12-01 RU RU2015144809A patent/RU2711869C3/ru active Protection Beyond IP Right Term
- 2010-12-01 PT PT108350612T patent/PT2506716T/pt unknown
- 2010-12-01 CN CN201080062920.6A patent/CN102711476B/zh active Active
- 2010-12-01 SG SG10201407976UA patent/SG10201407976UA/en unknown
- 2010-12-01 CA CA2991896A patent/CA2991896A1/en not_active Abandoned
- 2010-12-01 TW TW104119191A patent/TWI600656B/zh not_active IP Right Cessation
- 2010-12-01 KR KR1020177027803A patent/KR20170118230A/ko not_active Abandoned
- 2010-12-01 PL PL10835061T patent/PL2506716T3/pl unknown
- 2010-12-01 RU RU2012127306A patent/RU2570416C9/ru not_active IP Right Cessation
- 2010-12-01 SI SI201031517T patent/SI2506716T1/sl unknown
- 2010-12-01 CN CN201410571754.2A patent/CN104370909B/zh active Active
- 2010-12-01 MX MX2012006311A patent/MX346959B/es active IP Right Grant
- 2010-12-01 KR KR1020127017105A patent/KR101785257B1/ko active Active
- 2010-12-01 ME MEP-2017-167A patent/ME02800B/me unknown
- 2010-12-01 PH PH1/2012/501076A patent/PH12012501076B1/en unknown
- 2010-12-01 EP EP21173353.0A patent/EP3950692A1/en active Pending
-
2012
- 2012-05-29 IL IL220054A patent/IL220054A/en active Protection Beyond IP Right Term
- 2012-05-30 DO DO2012000151A patent/DOP2012000151A/es unknown
- 2012-05-30 CL CL2012001397A patent/CL2012001397A1/es unknown
- 2012-05-31 ZA ZA2012/03999A patent/ZA201203999B/en unknown
- 2012-06-18 EC ECSP12011979 patent/ECSP12011979A/es unknown
- 2012-06-22 CO CO12105210A patent/CO6561771A2/es active IP Right Grant
- 2012-06-25 CR CR20120348A patent/CR20120348A/es unknown
-
2013
- 2013-02-07 US US13/761,501 patent/US20130216497A1/en not_active Abandoned
-
2014
- 2014-08-26 JP JP2014171336A patent/JP5985557B2/ja not_active Expired - Fee Related
-
2016
- 2016-01-14 DO DO2016000017A patent/DOP2016000017A/es unknown
- 2016-02-08 US US15/017,802 patent/US20160222020A1/en not_active Abandoned
- 2016-03-23 AU AU2016201825A patent/AU2016201825B2/en active Active
- 2016-05-27 PH PH12016501009A patent/PH12016501009A1/en unknown
- 2016-08-02 JP JP2016151711A patent/JP6298114B2/ja not_active Expired - Fee Related
- 2016-10-25 IL IL248466A patent/IL248466A/en active IP Right Review Request
-
2017
- 2017-03-01 US US15/446,102 patent/USRE47221E1/en active Active
- 2017-07-16 IL IL253516A patent/IL253516B/en unknown
- 2017-07-31 CY CY20171100817T patent/CY1119175T1/el unknown
-
2018
- 2018-03-07 AU AU2018201663A patent/AU2018201663B2/en active Active
- 2018-09-13 IL IL261778A patent/IL261778A/en unknown
- 2018-12-14 HK HK18116085.2A patent/HK1256947A1/zh unknown
-
2019
- 2019-06-13 US US16/440,442 patent/US20210061813A1/en not_active Abandoned
-
2020
- 2020-02-26 AU AU2020201390A patent/AU2020201390A1/en not_active Abandoned
- 2020-03-09 LU LU00149C patent/LUC00149I2/fr unknown
- 2020-03-11 HU HUS2000008C patent/HUS000500I2/hu unknown
- 2020-03-11 NO NO2020006C patent/NO2020006I1/no unknown
- 2020-03-16 CY CY2020007C patent/CY2020007I2/el unknown
- 2020-03-17 LT LTPA2020505C patent/LTC2506716I2/lt unknown
- 2020-03-17 NL NL301035C patent/NL301035I2/nl unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013512280A5 (https=) | ||
| RU2015144809A (ru) | Новые трициклические соединения | |
| RU2010153582A (ru) | Новые трициклические соединения | |
| KR101585848B1 (ko) | 관절염의 치료 방법 | |
| CA2820618C (en) | Use of sulfonylbenzamide compounds in the treatment of systemic lupus erythematosus, lupus nephritis, or sjogren's syndrome | |
| US20080182845A1 (en) | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection | |
| JP2016539927A (ja) | Ｊａｋ１選択的阻害剤とその使用 | |
| WO2012127506A4 (en) | Substituted fused tricyclic compounds, compositions and medicinal applications thereof | |
| US11382907B2 (en) | Methods and compositions for treating aging-associated impairments using CCR3-inhibitors | |
| JP2013515074A5 (https=) | ||
| JP2010540527A (ja) | ケモカイン受容体拮抗薬としてのオクタヒドロペンタレン化合物 | |
| US20160175316A1 (en) | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection | |
| US20200054622A1 (en) | Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-Inhibitors | |
| TWI797366B (zh) | 吡咯并[1,2-b]嗒衍生物 | |
| EP3856195A1 (en) | Methods and compositions for treating aging-associated impairments using ccr3-inhibitors | |
| HK1243076A1 (zh) | 作為布羅莫結構域抑制劑的取代的吡咯並吡啶 | |
| HK1243072A1 (zh) | 布罗莫结构域抑制剂及其用途 | |
| HK1224937B (en) | Methods of treatment using selective bcl-2 inhibitors |